The total income of the company was at Rs598 mn, registering a growth of 5.3% yoy. Profit after Tax stood at Rs73 mn, registering a growth of 82.3% yoy. EPS was Rs2.79 as compared to Rs1.53; a growth of 82.3%.
The company reported an EBITDA of Rs106 mn, up 101.3% yoy translating to an EBITDA margin of 17.7%. This was an increase in the margin of 844 bps.
EBITDA margin improved due to:
- Increase in sale of high margin products
- Improvement in the ratio of manufacturing cost overheads as a percentage of the sale
- Better financial control and monitoring of other administrative expenses
Jagsonpal Pharmaceuticals, said.
“The board has approved an Interim Dividend at 80% per Equity Shares of face value of Rs5/-, which translates to Rs4 per equity share. The decision was taken by the board keeping in mind the excess cash in the balance sheet with no immediate capex plans in the horizon. The board will continue to assess the cash situation and reward shareholders after meeting all the needs of the Company.
In keeping with its strategy for growth, the Company has engaged Accenture to review and chalk out a business transformation plan with a focus on revenue growth, cost optimization and building organization enablers,” Kochhar added.